NCT04061395View on ClinicalTrials.gov

Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study.

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

December 30, 2021

Study Completion Date

April 1, 2022

Conditions
Hidradenitis Suppurativa
Interventions
BIOLOGICAL

Guselkumab

See study arm description.

Trial Locations (2)

Unknown

Erasmus MC, University Medical Center Rotterdam, Rotterdam

9713 GZ

University Medical Center Groningen, Groningen

All Listed Sponsors
collaborator

Janssen-Cilag Ltd.

INDUSTRY

lead

University Medical Center Groningen

OTHER

NCT04061395 - Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study. | Biotech Hunter | Biotech Hunter